The Impact of Pathological Response of Primary Tumor in Patients with Locally Advanced Breast Cancer Who Reached Axillary Pathological Complete Response (pcr) after Neoadjuvant Chemotherapy

Z. Zhou,J. Luo,X. Chen,Z. Yang,J. Ma,X. Mei,L. Zhang,Q. C. Hu,X. Guo,X. Yu

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.700

2016-01-01

Abstract:To evaluate the impact of pathologic response of primary tumor on disease-free survival (DFS) and overall survival (OS) in patients with locally advanced breast cancer (LABC) and reached axillary pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). From January 2008 to June 2013, 210 patients who received NAC in Fudan University Shanghai Cancer Center and reached axillary pCR after operation were retrospectively analyzed regarding to the prognostic significance of achieving a pCR or not in primary tumor. Those patients were diagnosed as clinical stage II-III breast cancer and primary tumor and lymph nodes were confirmed by core needle biopsy before NAC. Clinical stage was assessed by physical examination and imaging procedures. Axillary lymph nodes and primary tumors response to NAC were assessed via histopathology after surgery. Axillary pCR was defined as no invasive lymph nodes were detected after axillary lymph nodes dissection or sentinel lymph node biopsy. No residual invasive carcinoma or only residual ductal carcinoma in situ (DCIS) in primary tumor tissue was considered as pCR in primary tumor. Patients were divided into two groups for statistical analysis, according to whether they reached pCR or not in primary tumor. The groups were compared in terms of DFS and OS. The median follow-up time was 35 months (range, 6-100 months). Median age of 210 patients was 50 years olds (range, 24-80 years old). 107 (51%) patients were hormone receptor positive and 72 (34.4%) of them were Her2 positive. All patients received NAC and 188 (89.5%) of whom received NAC based on paclitaxel and carboplatin, the median course was 4. 192 (91.4%) patients received postoperative chemotherapy and 151 (76.6%) patients received radiation therapy. Almost all hormone receptor positive patients (104/107) received hormone therapy and only 40.3% (29/72) Her2 positive patients received Herceptin therapy. Of all patients, 42.9% (90/210) reached pCR in primary tumor, who had favorable DFS compared with non-pCR ones (Hazard ratio: 0.4024, 95% confidence interval [CI] 0.1699-0.9530, P = 0.0658). OS didn’t show significant difference between two groups (HR: 0.2723, 95% [CI] 0.05391-1.3749, P = 0.2029). Postoperative radiation therapy significantly improved DFS in patients with residual tumor (HR: 0.2782, 95% [CI] 0.0777-0.9959, P = 0.0077), but didn’t improve OS (HR: 0.7971 95% [CI] 0.0719-8.8427, P = 0.8436). Because of relative low sample size in primary tumor pCR patients, radiation therapy improved neither DFS nor OS. Primary tumor pCR was a favorable factor for prognosis in patients who reached axillary pCR after NAC. Patients with residual tumor tend to have lower DFS compared with primary tumor pCR ones, but radiation therapy could improve DFS for them.